Lung cancer is the most common cause of cancer deaths worldwide, with more than 1.8 million people diagnosed worldwide each year. It causes more deaths than breast and prostate cancers combined. It has a dismal 5 year survival rate of just 18%, compared to 99% for prostate and 89% for breast cancer.
The introduction of screening programmes to diagnose lung cancer early, provides the opportunity for a paradigm shift in the treatment. This will require new and innovative treatments that are that are both clinically effective and reduce the burden on healthcare systems.
Chemotherapy is an established treatment for lung cancer, particularly for later stage disease. Generally 4-6 treatment cycles are needed, which can be combined with other approaches including surgery, radiation or ablation therapy.
Surgical interventions are costly (>$20k) and invasive but can offer a curative solution. Unfortunately, less than 15% of patients are suitable for surgery due to comorbidities.
Advances in radiation therapy, including Stereotactic Body Radiation Therapy (SBRT) have been shown to significantly improve survival rates. However, the treatment is expensive and requires specialist clinical expertise, meaning that it has remained confined to a small number of specialist centres.
Percutaneous microwave ablation has been shown to have good clinical efficacy. However, up to 50% of patients suffer a collapsed lung (pneumothorax) caused by inserting the probe through the chest wall, limiting its adoption.
We have developed a fully flexible microwave ablation catheter system that can be delivered through the patient’s airways to reach the target disease. It will allow physicians to completely destroy a tumour in a single intervention using a minimally invasive approach.
With our innovative antenna design and deployable cooling system technology, we have achieved a ground-breaking 19 gauge ablation needle tip that is fully flexible for navigation through a tortuous path. Our patented technology ensures fast and reliable ablation in lung tissue.
Our device is designed for delivery through patient's airways using commercially available navigation bronchoscopy systems. This procedure can be carried out with mild sedation in an outpatient setting.
Transbronchial microwave ablation will enable a treatment to be delivered at a lower cost than alternatives including surgery or SBRT, with quickier patient recovery and a shorter hospital length of stay.
When combined with existing biopsy devices, our flexible microwave ablation system provides the opportunity for diagnosis and treatment in a single intervention, with associated improvements to patient care and outcomes.
Our approach leverages existing technical and clinical data from microwave ablation to maximise safety for patients. Our system is fully cooled to ensure a precise ablation and to protect healthy tissue.
Endowave is a technology driven company focused on delivering the best in class flexible ablation catheter system. The founders are alumni of the Bioinnovate programme which is affiliated with Stanford Biodesign, which provides a structured approach to medtech innovation. We are located within the medical device industry cluster, in Galway, Ireland.
With over 20 years experience in the medtech sector, Jonathan leads all commercial activities including fundraising, partnering and contract negotiation.
Jimmy has over 15 years of experience of medical device product development in both start-up and multi-nationals. He leads all mechanical design activities and project management.
Giuseppe is a leading expert in microwave ablation technology with over 15 years of experience in antenna design. He leads all electronics related design activities including design and simulation.